Attention-deficit hyperactivity disorder and the athlete: New advances and understanding

Clinics in Sports Medicine

Volumn 30, Issue 3, 2011, Pages 591-610

  Parr, Jesse W ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

ADHD; Drug therapy; Exercise physiology; Sports; Thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; COCERTA; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOCOSAHEXAENOIC ACID; GUANFACINE; ICOSAPENTAENOIC ACID; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

APPETITE; ATHLETE; ATHLETIC PERFORMANCE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EMOTIONAL DISORDER; FUNCTIONAL DISEASE; HEART PROTECTION; HUMAN; HYPOTENSION; INCIDENCE; NEUROTRANSMISSION; ONSET AGE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ATHLETES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS;

EID: 79958164898     PISSN: 02785919     EISSN: 1556228X     Source Type: Journal    
DOI: 10.1016/j.csm.2011.03.007     Document Type: Review

References (63)

1. NCAA Banned Drugs and Medical Exceptions Policy Guidelines Regarding Medical Reporting for Student-Athletes with Attention Deficit Hyperactivity Disorder (ADHD) Taking Prescribed Stimulants. The National Collegiate Athletic Association Available at:, Accessed November 9, 2010; and Addendum to the January 2009 Guidelines Q&A March 2009. Accessed November 9, 2010. http://www.ncaa.org.
2. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723.
3. Diagnostic and statistical manual of mental disorders 2000, Text revision, American Psychiatric Publishing, Inc, Arlington (VA). 4th edition.
4. Barkley R.A. Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry 2010, 71(7):e17.
5. Boonstra A.M., Osterlaan J., Sergeant J.A., et al. Executive functioning in adult ADHD: a meta-analytic review. Psychol Med 2005, 35(8):1097-1108.
6. Liotti M., Pliszka S.R., Perer R., et al. Electrophysiological correlates of response inhibition in children and adolescents with ADHD: influence of gender, age and previous treatment history. Psychophysiology 2007, 44(6):936-948.
7. Kuntsi J., McLoughlin G., Asherson P. Attention deficit hyperactivity disorder. Neuromolecular Med 2006, 8(4):461-484.
8. Emond V., Joyal C., Poissant H. Encephale 2009, 35(2):107-114. [abstract], [in French]. Accessed November 9, 2010.
9. Bush G., Frazier J.A., Rauch S.L., et al. Anterior cingulated cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry 1999, 45(12):1542-1552.
10. Castellanos R.X., Lee P.P., Sharp W., et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002, 288:1740-1748.
11. Seidman L.J., Valera E.M., Makris N., et al. Dorsolateral prefrontal and anterior cingulated cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biol Psychiatry 2006, 60(10):1071-1080.
12. Silk T.J., Vance A., Rinehart N., et al. White-matter abnormalities in attention deficit hyperactivity disorder: a diffusion tensor imaging study. Hum Brain Mapp 2009, 30(9):2757-2765.
13. Makris N., Buka S.L., Biederman J., et al. Attention and executive systems abnormalities in adults with childhood ADHD: a DT-MRI study of connections. Cereb Cortex 2008, 18(5):1210-1220.
14. Bush G., Valera E.M., Seidman L.J. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 2005, 57(11):1273-1284.
15. Konrad K., Eickoff S.B. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp 2010, 31(6):904-916.
16. Shaw P., Eckstrand K., Sharp W., et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A 2007, 104(49):19649-19654.
17. Shaw P., Rabin C. New insights into attention-deficit/hyperactivity disorder using structural neuroimaging. Curr Psychiatry Rep 2009, 11(5):393-398.
18. Biederman J., Monuteaux M.C., Spencer T., et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009, 124(1):71-78.
19. Biederman J., Faraone S.V., Spencer T.J., et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006, 67:524-540.
20. Barkley R.A., Murphy K.R., Dupaul G.I., et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002, 8(5):655-672.
21. Biederman J., Wilens T.E., Mick E., et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?. Biol Psychiatry 1998, 44(4):269-273.
22. Biederman J., Monuteaux M.C., Mick E., et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006, 36(2):167-179.
23. Milberger S., Biederman J., Faraone S.V., et al. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children?. Am J Psychiatry 1996, 153(9):1138-1142.
24. Faraone S.V., Perlis R.H., Doyle A.E., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1313-1323.
25. Faraone S.V., Sergeant J., Gillberg C., et al. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2(2):104-113.
26. Faraone S.V., Biederman J., Spencer T., et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid?. Am J Psychiatry 2006, 163(10):1720-1729.
27. Fliers E., Rommelse N., Vermeulen S.H., et al. Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender. J Neural Transm 2008, 115(2):211-220.
28. Pitcher T.M. Fine and gross motor ability in males with ADHD. Dev Med Child Neurol 2003, 45(8):525-535.
29. Kiluk B.D., Weden S., Culotta V.P. Sport participation and anxiety in children with ADHD. J Atten Disord 2009, 12(6):499-506.
30. Bush G., Spencer T.J., Holmes J., et al. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry 2008, 65(1):102-114.
31. Rubia K., Halari R., Cubillo A., et al. Methylphenidate normalizes activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009, 57(7-8):640-652.
32. Arntsen A.F. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009, 23(Suppl 1):33-41.
33. May D.E., Kratochvil C.J. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010, 70(1):15-40.
34. Brennan A.R., Arntsen A.F. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 2008, 1129:236-245.
35. Shaw P., Sharp W.S., Morrison M., et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am J Psychiatry 2009, 166(1):58-63.
36. Wigal S.B. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009, 23(Suppl 1):21-31.
37. Johnson M., Ostlund S., Fransson G., et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009, 12(5):394-401.
38. Richardson A.J., Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115(5):1360-1366.
39. Richardson A.J. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006, 18(2):155-172.
40. Germano M., Meleleo D., Montorfano G., et al. Plasma, red blood cells phospholipids and clinical evaluation after long chain omega-3 supplementation in children with attention deficit hyperactivity disorder (ADHD). Nutr Neurosci 2007, 10(1-2):1-9.
41. Schuchardt J.P., Huss M., Stauss-Grabo M., et al. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behavior of children. Eur J Pediatr 2010, 169(2):149-164.
42. Kirby A., Woodward A., Jackson S., et al. Childrens' learning and behavior and the association with cheek cell polyunsaturated fatty acid levels. Res Dev Disabil 2010, 31(3):731-742.
43. Gehricke J.G., Whalen C.K., Jamner L.D., et al. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: a preliminary examination. Nicotine Tob Res 2006, 8(1):37-47.
44. Gehricke J.G., Hong N., Whalen C.K., et al. Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder. Psychol Addict Behav 2009, 23(4):644-655.
45. Gehricke J.G., Louglin S.E., Whalen Ck, et al. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob Res 2007, 9(Suppl 4):S523-S536.
46. Volkow N.D., Ding Y.S., Fowler J.S., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psych 1995, 52(6):456-463.
47. Chandler J.V., Blair S.N. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc 1980, 12(1):65-69.
48. Meeusen R., Watson P., Hasegawa H., et al. Central fatigue: the serotonin hypothesis and beyond. Sports Med 2006, 36(10):881-909.
49. Watson P., Hasegawa H., Roelands B., et al. Acute dopamine/norepinephrine reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. J Physiol 2005, 565(pt 3):873-883.
50. Swart J., Lamberts R.P., Lambert M.I., et al. Exercising with reserve: evidence that the central nervous system regulates prolonged exercise performance. Br J Sports Med 2009, 43:782-788.
51. Roelands B., Hasegawa H., Watson P., et al. The effects of acute dopamine reuptake inhibition on performance. Med Sci Sports Exerc 2008, 40(5):879-885.
52. Roelands B., Hasegawa H., Watson P., et al. Performance and thermoregulatory effects of chronic bupropion administration in the heat. Eur J Appl Physiol 2009, 105(3):493-498.
53. Roelands B., Goekint M., Heyman E., et al. Acute norepinephrine reuptake inhibition decreases performance in normal and high ambient temperature. J Appl Physiol 2008, 105(1):206-212.
54. Mahon A.D., Stephens B.R., Cole A.S. Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication. J Atten Disord 2008, 12(2):170-176.
55. Mills E.M., Rusyniak D.E., Sprague J.E. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med 2004, 82(12):787-799.
56. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004, 50(4):329-335.
57. Vetter V.L., Elia J., Erickson C., et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008, 117(18):2407-2423.
58. Pliszka S., American Academy of Child and Adolescent Psychiatry, Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46(7):894-921.
59. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000, 105(5):1158-1170.
60. Denchev P., Kaltman J.R., Schoenbaum M., et al. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010, 121(11):1329-1337.
61. TUEs and Medical Declarations; TUEs FAQs. United States Anti-Doping Agency Available at:, Accessed November 9, 2010. http://www.usada.org/tue-faq.
62. USADA Policy for Therapeutic Use Exemptions and Declaration of Use. United States Anti-Doping Agency Available at:, Accessed September 17, 2010. http://www.usada.org/tue-policy/.
63. Documentation to support a Therapeutic Use Exemption application for stimulants to treat ADD/ADHD. United States Anti-Doping Agency Available at:, Accessed September 17, 2010. http://www.usada.org/files/pdfs/TUEhowto.pdf.